TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05666141

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pharyngeal Electrical Stimulation
Description: A Phagenyx catheter is inserted trans-nasally. The catheter design incorporates a nasogastric feeding tube with built-in stimulation electrodes. The intervention consists of 3 PES sessions. A session is a 10-minute stimulation, once per day. The sessions will be given on three consecutive days at optimal parameters.

Intervention type: OTHER
Group type: OTHER
Intervention: Sham treatment
Description: In the Sham condition, the same method and same device will be used. The time spent interacting with the patient will remain constant, including placement of the PES catheter which will be left in situ in the subject for the duration of intervention (10 minutes). However, the base-station will be set to 0 milliampere (mA), so Sham subjects do not receive any active electrical current.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham treatment
Description: In the Sham condition, the same method and same device will be used. The time spent interacting with the patient will remain constant, including placement of the PES catheter which will be left in situ in the subject for the duration of intervention (10 minutes). However, the base-station will be set to 0 milliampere (mA), so Sham subjects do not receive any active electrical current.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: In the Sham condition, the same method and same device will be used. The time spent interacting with the patient will remain constant, including placement of the PES catheter which will be left in situ in the subject for the duration of intervention (10 minutes). However, the base-station will be set to 0 milliampere (mA), so Sham subjects do not receive any active electrical current.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: In the Sham condition, the same method and same device will be used. The time spent interacting with the patient will remain constant, including placement of the PES catheter which will be left in situ in the subject for the duration of intervention (10 minutes). However, the base-station will be set to 0 milliampere (mA), so Sham subjects do not receive any active electrical current.
Study: NCT05561582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seated knee extension exercise
Description: Participants will be seated in a resistance exercise machine. Weight corresponding to the assigned group will be added to the machine. Participants will extend the dominant knee for 3 sets of 10 repetitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seated knee extension exercise
Description: Participants will be seated in a resistance exercise machine. Weight corresponding to the assigned group will be added to the machine. Participants will extend the dominant knee for 3 sets of 10 repetitions.
Study: NCT05113446

Intervention type: DIAGNOSTIC_TEST
Intervention: Delirium assessment using S-CAM
Description: Twice a day, the rounds of nurses in shifts, 8:00 am - 10:00 am, 4:00 pm - 6:00 pm Trained research assistants assessed delirium using S-CAM
Study: NCT06090110

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vagal Nerve Stimulation
Description: Transcutaneous Auricular Vagal Nerve Stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham stimulation
Description: Sham stimulation with a non-conduction electrode
Study: NCT04817826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: durvalumab 1500 mg Q4W for 3 cycles (day 1, 29 and 57).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: durvalumab 1500 mg Q4W for 3 cycles (day 1, 29 and 57).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: tremelimumab 300 mg single administration (day 1)
Study: NCT06166680

Intervention type: OTHER
Intervention: Sleep quality assessment
Description: The following item will be assessed in all subjects (n=420):~1. Sleep, through the Pediatric Sleep Questionnaire.

Intervention type: OTHER
Intervention: Anthropometry
Description: The following items will be assessed in all subjects (n=420):~2. Anthropometric data : 2.1 Height; 2.2 Weight; 2.3 Maximal mouth opening; 2.4 Maximal mouth opening with tongue to palate (with the Quick Tongue-Tie assessment tool)

Intervention type: OTHER
Intervention: Tongue strength assessment
Description: The following items will be assessed in all subjects (n=420):~3. Tongue pressure (in kPa) exerted against the IOPI (Iowa Oral Performance Instrument) bulb while swallowing.~4. Tongue peak pressure (i.e., the maximal pressure - Pmax - exerted against the IOPI bulb) during 3 sec. of tongue elevation.~5. Tongue peak pressure during 3 sec. of tongue protrusion.

Intervention type: OTHER
Intervention: Tongue endurance assessment
Description: The following items will be assessed in all subjects (n=420):~6. The tongue endurance (i.e., the time to task failure in maintaining a pressure equal to 50%Pmax against the IOPI bulb) during tongue elevation.~7. The tongue endurance during tongue protrusion.

Intervention type: OTHER
Intervention: Orofacial praxis assessment
Description: - The following item will be assessed in a subset of subjects (n=31): 8. Orofacial praxis through the Motricité Bucco-Linguo-Faciale (MBLF) test.
Study: NCT04726722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: internet-based cognitive behavioral theraphy
Description: When determining the content of the I-CBT program, the participants and therapist will be allowed to choose from a library of treatment modules.~Therapist controlled support and feedback are given weekly and in a structured manner. Participants will be able to contact the therapist when support and feedback is desired

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: internet-based cognitive behavioral theraphy
Description: When determining the content of the I-CBT program, the participants and therapist will be allowed to choose from a library of treatment modules.~Therapist controlled support and feedback are given weekly and in a structured manner. Participants will be able to contact the therapist when support and feedback is desired
Study: NCT05322200

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: A computerized tomography (CT) coronary angiogram
Description: Participants in both arms will undergo CT coronary angiogram with Plaque Map analysis at baseline prior to therapy initiation and following 12 months of treatment.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: A computerized tomography (CT) coronary angiogram
Description: Participants in both arms will undergo CT coronary angiogram with Plaque Map analysis at baseline prior to therapy initiation and following 12 months of treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vicorder (Skidmore medical, UK)
Description: Participants in both arms will undergo aortic carotid-femoral pulse wave velocity (cfPWV)through the Vicorder (Skidmore medical, UK), which uses oscillometric cuff-based measurements to establish the index of arterial stiffness. The procedure will be done at baseline and 12 months after therapy initiation.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Vicorder (Skidmore medical, UK)
Description: Participants in both arms will undergo aortic carotid-femoral pulse wave velocity (cfPWV)through the Vicorder (Skidmore medical, UK), which uses oscillometric cuff-based measurements to establish the index of arterial stiffness. The procedure will be done at baseline and 12 months after therapy initiation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood tests for inflammation and oxidative stress markers
Description: All the participants will have (non-fasting) blood samples performed to assess serum glucose, lipid profile and serum biomarkers for plaque initiation (Lipid profile, LpPLA2), endothelial activation (MCP-1), plaque inflammation (hsCRP, IL6, IL18, TNF, advanced glycation end-products), vulnerable transformation (vEGF, PAI-1, BMP-6) and measures of oxidative stress (Ox-LDL, TAOS, TBARs) at baseline, and at 12 months after therapy initiation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blood tests for inflammation and oxidative stress markers
Description: All the participants will have (non-fasting) blood samples performed to assess serum glucose, lipid profile and serum biomarkers for plaque initiation (Lipid profile, LpPLA2), endothelial activation (MCP-1), plaque inflammation (hsCRP, IL6, IL18, TNF, advanced glycation end-products), vulnerable transformation (vEGF, PAI-1, BMP-6) and measures of oxidative stress (Ox-LDL, TAOS, TBARs) at baseline, and at 12 months after therapy initiation
Study: NCT05292248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Confidently Navigating Financial Decisions and Enhancing Financial Wellbeing in Dementia Caregiving
Description: Multicomponent psychoeducational intervention focused on financial wellbeing
Study: NCT05065359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rodatristat Ethyl 300 mg BID
Description: Tablets, oral, 300 mg, BID 14 days
Study: NCT05804123

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl physiological saline Nasal-spraying
Description: 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl physiological saline Nasal-spraying
Description: 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
Study: NCT05065359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rodatristat Ethyl 300 mg BID
Description: Tablets, oral, 300 mg, BID 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rodatristat Ethyl 600 mg BID
Description: Tablets, oral, 600 mg, BID 14 days
Study: NCT05804123

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LiveSpo Navax®
Description: In Vietnam, LiveSpo Navax® is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LiveSpo Navax®
Description: In Vietnam, LiveSpo Navax® is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Augmentin 500Mg Tablet
Description: Augmentin (GlaxoSmithKline Pte, product declaration No. VN-20169-16) is an oral antibiotic available in the form of 625 mg tablets, which are prescribed as routine treatment for children and adults, respectively.
Study: NCT05065359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rodatristat Ethyl 600 mg BID
Description: Tablets, oral, 600 mg, BID 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, oral, 0 mg, BID for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, oral, 0 mg, BID for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, oral, 0 mg, BID for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, oral, 0 mg, BID for 14 days
Study: NCT06504810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: light
Description: light level
Study: NCT04817826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: tremelimumab 300 mg single administration (day 1)
Study: NCT06482931

Intervention type: OTHER
Intervention: Quality of life questionnaires
Description: Patients will be asked to fill in two quality of life questionnaires: PACT-Q and EQ-5D-5L.

Intervention type: OTHER
Intervention: Quality of life questionnaires
Description: Patients will be asked to fill in two quality of life questionnaires: PACT-Q and EQ-5D-5L.
Study: NCT06375057

Intervention type: PROCEDURE
Intervention: laparoscopic cholecystectomy
Description: A blood sample is taken the day after surgery
Study: NCT05804123

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Augmentin 500Mg Tablet
Description: Augmentin (GlaxoSmithKline Pte, product declaration No. VN-20169-16) is an oral antibiotic available in the form of 625 mg tablets, which are prescribed as routine treatment for children and adults, respectively.
Study: NCT06504810

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: light
Description: light level
Study: NCT06309563

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aminoacid supplementation
Description: Low-calorie and low-protein diet + with 4 sachets of EEA-AC supplement per day for 2 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Low-calorie and low-protein diet + placebo for 2 weeks
Study: NCT05274958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-rated outcome measures and educational videos
Description: PROMs are scales that are validated in behavioral health for tracking symptoms of depression, anxiety, and other conditions. They can be self-administered or given by a clinician. Mytonomy videos are short, educational videos about the patient's primary condition. All patients receive PROMs on entering our clinic. The difference in this intervention is those randomized to the active treatment will receive monthly PROMs and mytonomy video(s) until their appointment with the clinician. Usual care patients will only have PROMs at the intake and then at the appointment with their assigned clinician.
Study: NCT06172179

Intervention type: OTHER
Intervention: No interventions
Description: All procedures are observation. No intervention in this study.

Intervention type: OTHER
Intervention: No interventions
Description: All procedures are observation. No intervention in this study.

Intervention type: OTHER
Intervention: No interventions
Description: All procedures are observation. No intervention in this study.
Study: NCT05804123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Ciprofloxacin 0.3% (Vidipha Central Pharmaceutical, product declaration No. VD-15205-11) is an antibiotic ear drop, which is prescribed as routine treatment for children.
Study: NCT06466967

Intervention type: DEVICE
Intervention: Advanced hybrid closed-loop CamAPS FX
Description: Treatment with a strict programmed glucose target (80-99 mg/dL).
Study: NCT04913311

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood, saliva, stool, and bronchoalveolar lavage samples
Study: NCT04889508

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Socio-emotional mental training
Description: Core practice: Affect Dyad. In the Affect Dyad (AD), participants perform a 12-minute partner-based exercise which involves contemplating over one difficult situation and one situation which incurred gratitude in the past 24 hours. Both partners take turns speaking about the two situations while the other partner listens in a non-judgmental manner. While the participants elaborate on the situations, they are asked to focus on the bodily experience of the emotions generated during the situation. The goal of the exercise is to enhance coping with difficult emotions, empathic listening, social sharing, acceptance, and gratitude.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Socio-emotional mental training
Description: Core practice: Affect Dyad. In the Affect Dyad (AD), participants perform a 12-minute partner-based exercise which involves contemplating over one difficult situation and one situation which incurred gratitude in the past 24 hours. Both partners take turns speaking about the two situations while the other partner listens in a non-judgmental manner. While the participants elaborate on the situations, they are asked to focus on the bodily experience of the emotions generated during the situation. The goal of the exercise is to enhance coping with difficult emotions, empathic listening, social sharing, acceptance, and gratitude.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based mental training
Description: Core practice: Breathing Meditation. In this intervention, participants will practice 12-minute basic attention-based mindfulness meditation such as the Breathing Meditation (BM). BM is a 12-minute individual exercise that requires participants to focus their attention on the sensations of breathing. Participants have to sustain their attention to breath for long stretches of time, and have to return their attention to their breath when their mind wanders. The key focus is on training attention and interoceptive body awareness. Other practices participants will be taught is mindfulness on sounds (here the object of attention is not the breath but sounds in the environment).
Study: NCT04913311

Intervention type: PROCEDURE
Intervention: Bronchoscopy with Bronchoalveolar Lavage
Description: Undergo bronchoscopy with BAL
Study: NCT05630950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smoking cessation mobile application
Description: Mobile application for smoking cessation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written material for smoking cessation
Description: Written material for smoking cessation
Study: NCT04913311

Intervention type: OTHER
Intervention: Chemoradiotherapy
Description: Undergo concurrent chemoradiation per standard of care

Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Undergo computed tomography scan
Study: NCT05553925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Weight Management Program with Coaching and Patient Navigator Support
Description: Patients will enroll in a 12-month digital health program available in online and mobile versions with live, personalized coaching and patient navigator support.~Patient Interface~* Digital scale and Fitbit~* Brief lessons that focus on helping patients improve their nutrition, exercise, sleep, and stress~* Weight, diet, and physical activity tracking~* Regular, personalized feedback and support from a health coach~* Spanish Version~Patient navigators are non-licensed staff. Their responsibilities will include enrolling patients in the program, monitoring their progress, and updating providers periodically. They also will be able to connect patients with additional resources and services, such as the Center for Weight Management and Wellness, if appropriate.
Study: NCT04913311

Intervention type: OTHER
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Intervention: Immune Checkpoint Inhibitor
Description: Receive CPI per standard of care

Intervention type: PROCEDURE
Intervention: Nasal Wash and Collection
Description: Undergo nasal wash

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Intervention: Spirometry
Description: Under lung spirometry tests
Study: NCT06701149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rademikibart injection
Description: 300 mg administered subcutaneously on the first day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBP-201 injection
Description: 300 mg administered subcutaneously on the first day
Study: NCT06695988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating
Description: The intervention group will eat and drink in a prescribed daily feeding window of 8-hour between 6 a.m. to 8 p.m. for 8 weeks and follow their normal exercise and resistance training routines. We will allow +/-1 hour starting and ending times for the eating window while aiming for an 8-hour eating window
Study: NCT06721884

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artemisia Annua Leaf
Description: The intervention is Artecinua™ which is an organic Artemisia annua dried leaf powder in a vegan / kosher/ halal capsule. Artemisia annua L is classified as a 'generally regarded as safe' (GRAS) herb. Participants will be instructed to wean up to a full 5g dose by the following schedule.~1. gram (3 caps) 1st day,~2. grams (6 caps) 3/am, 3/pm, for the 3rd day,~3. grams (9 caps) 3/am 3/noon 3/pm for the 5th day,~4. grams (12 caps) 4/am, 4/noon, 4/pm for the 7th day,~5. grams (15 caps) 5/am, 5/noon, 5/pm for rest of intervention period (4 weeks)~Containers of ArtecinuaTM will be kept in a secured cabinet before being administered, under climate-controlled conditions, and checked weekly to ensure consistent ambient temperature.~The justification of the 5g a day dosing is based on empiric experience and is in line with recommended dosages by the pharmacopeia of the People's Republic of China and has been previously used in clinical trials

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: We have chosen dried-leaf alfalfa of equal weight and dosing to the interventional product (5 grams, 15 caps, 5/am, 5/noon, 5/pm for the 4 weeks of the intervention period plus an additional 1 week dose escalation period to match the dosing of the Artemisia product). We have chosen this as a comparator in consultation with SIBO and herbal medicine content experts as alfalfa matches the texture and color of Artemisia annua and, in the doses used, will provide no meaningful amounts of FODMAPs or antimicrobial phytochemicals. The alfalfa will be sourced from Bulk Apotherapy, LCC, and encapsulated at the same facility as the Artemisia capsules. Containers of placebo capsules will be kept in a secured cabinet before being administered, under climate-controlled conditions, and checked weekly to ensure consistent ambient temperature.
Study: NCT06720064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Dressing
Description: Transparent catheter cover with Chlorhexidine (3M™ CHG Tegaderm™)
Study: NCT06720883

Intervention type: PROCEDURE
Intervention: Major hepatectomy
Description: All patients will undergo robotic major hepatectomy with S1 resection, hilar lymphadenectomy and biliary reconstruction
Study: NCT06719752

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo intervention; the therapy will mimic exceptional mobilization.